Cellectis S.A. announces board change and meeting

Cellectis S.A. (NASDAQ:CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited T-cells, has reported a forthcoming change to its Board of Directors. The company, which generated revenues of $4.83 million in the last twelve months with an EBITDA of -$7.55 million, faces ongoing challenges in the competitive biotech sector. According to InvestingPro analysis, the company’s revenue showed an 11.94% decline year-over-year. Pierre Bastid will resign from his position on the board, effective as of the close of the upcoming Combined General Meeting of Shareholders. The resignation is not due to any disagreements with the company’s operations, policies, or practices. InvestingPro data shows the company maintains a FAIR financial health score of 1.99, suggesting stable corporate governance despite operational challenges.

The announcement came through a Form 6-K filing with the Securities and Exchange Commission dated May 21, 2025. This document is incorporated by reference into the company’s registration statements on Form F-3 and Form S-8, ensuring that the information is officially recorded and communicated to shareholders and potential investors.

The Combined General Meeting of Shareholders is scheduled for June 26, 2025, at 2:30 p.m. Paris time. It will be held at the Biopark auditorium in Paris, France. Shareholders and interested parties can access additional details about the meeting, including the Notice of Combined General Meeting and the text of resolutions, on Cellectis’s website in the Investors section.

The 6-K filing also includes the standard signatures and formalities required by the SEC, underscoring the authorized nature of the report and its adherence to the necessary regulatory framework.

This news comes as part of the company’s regular corporate governance updates and is based on the information provided in the SEC filing. Cellectis’s stock market investors and stakeholders will likely monitor the transition on the board and the outcomes of the forthcoming general meeting for insights into the company’s strategic direction. The company maintains a strong liquidity position with a current ratio of 3.05, while its beta of 0.55 indicates lower volatility compared to the broader market. For deeper insights into Cellectis’s financial health and growth prospects, investors can access additional metrics and analysis through InvestingPro.

In other recent news, Canadian Solar (NASDAQ:CSIQ) Inc. has submitted a Form 6-K to the U.S. Securities and Exchange Commission for May 2025. This filing includes the Notice of Annual Meeting of Shareholders and the Management Information Circular, essential documents for the company’s corporate governance. Glass House Brands Inc. also filed its interim financial statements with the SEC, providing a financial snapshot as of March 31, 2025. The report includes unaudited financial statements for the first quarter and management’s discussion on financial condition and operations. Triple Flag Precious Metals Corp. has reported its first-quarter financials to the SEC, including unaudited interim consolidated financial statements and management’s analysis of performance. These filings confirm the companies’ compliance with U.S. securities regulations, maintaining transparency and regulatory adherence. Investors and stakeholders are encouraged to review these documents for detailed financial and operational insights.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.